Literature DB >> 32029506

Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma.

Max S Topp1, Johannes Duell2, Ana Maria Abajo Guijarro3, Marielle Odin3, Tina Nielsen3, Anand Rajeswaran3, Michael Wenger3, Christelle Zundel3, Aleksandra Bogucka-Fedorczuk4, Tomasz Wrobel4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32029506      PMCID： PMC7193465          DOI： 10.3324/haematol.2019.233189

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

Review 1.  Cutaneous adverse effects of the immune checkpoint inhibitors.

Authors:  Lindsey K Collins; M Shane Chapman; Joi B Carter; Faramarz H Samie
Journal:  Curr Probl Cancer       Date:  2016-12-14       Impact factor: 3.187

Review 2.  The PD-1/PD-Ls pathway and autoimmune diseases.

Authors:  Suya Dai; Ru Jia; Xiao Zhang; Qiwen Fang; Lijuan Huang
Journal:  Cell Immunol       Date:  2014-05-27       Impact factor: 4.868

3.  CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease.

Authors:  Adèle de Masson; Jean-David Bouaziz; Hélène Le Buanec; Marie Robin; Alix O'Meara; Nathalie Parquet; Michel Rybojad; Estelle Hau; Jean-Benoît Monfort; Mylène Branchtein; David Michonneau; Valérie Dessirier; Flore Sicre de Fontbrune; Anne Bergeron; Raphaël Itzykson; Nathalie Dhédin; Djaouida Bengoufa; Régis Peffault de Latour; Aliénor Xhaard; Martine Bagot; Armand Bensussan; Gérard Socié
Journal:  Blood       Date:  2015-01-20       Impact factor: 22.113

Review 4.  PD-1/PD-L and autoimmunity: A growing relationship.

Authors:  Mohammad Reza Zamani; Saeed Aslani; Arash Salmaninejad; Mohammad Reza Javan; Nima Rezaei
Journal:  Cell Immunol       Date:  2016-09-15       Impact factor: 4.868

5.  Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy.

Authors:  Simone M Goldinger; Pascale Stieger; Barbara Meier; Sara Micaletto; Emmanuel Contassot; Lars E French; Reinhard Dummer
Journal:  Clin Cancer Res       Date:  2016-03-08       Impact factor: 12.531

6.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Authors:  Louis Fehrenbacher; Alexander Spira; Marcus Ballinger; Marcin Kowanetz; Johan Vansteenkiste; Julien Mazieres; Keunchil Park; David Smith; Angel Artal-Cortes; Conrad Lewanski; Fadi Braiteh; Daniel Waterkamp; Pei He; Wei Zou; Daniel S Chen; Jing Yi; Alan Sandler; Achim Rittmeyer
Journal:  Lancet       Date:  2016-03-10       Impact factor: 79.321

7.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Authors:  Arjun V Balar; Matthew D Galsky; Jonathan E Rosenberg; Thomas Powles; Daniel P Petrylak; Joaquim Bellmunt; Yohann Loriot; Andrea Necchi; Jean Hoffman-Censits; Jose Luis Perez-Gracia; Nancy A Dawson; Michiel S van der Heijden; Robert Dreicer; Sandy Srinivas; Margitta M Retz; Richard W Joseph; Alexandra Drakaki; Ulka N Vaishampayan; Srikala S Sridhar; David I Quinn; Ignacio Durán; David R Shaffer; Bernhard J Eigl; Petros D Grivas; Evan Y Yu; Shi Li; Edward E Kadel; Zachary Boyd; Richard Bourgon; Priti S Hegde; Sanjeev Mariathasan; AnnChristine Thåström; Oyewale O Abidoye; Gregg D Fine; Dean F Bajorin
Journal:  Lancet       Date:  2016-12-08       Impact factor: 79.321

Review 8.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

Authors:  J M Michot; C Bigenwald; S Champiat; M Collins; F Carbonnel; S Postel-Vinay; A Berdelou; A Varga; R Bahleda; A Hollebecque; C Massard; A Fuerea; V Ribrag; A Gazzah; J P Armand; N Amellal; E Angevin; N Noel; C Boutros; C Mateus; C Robert; J C Soria; A Marabelle; O Lambotte
Journal:  Eur J Cancer       Date:  2016-01-05       Impact factor: 9.162

9.  Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma.

Authors:  Yaqing Cao; Wenyi Lu; Rui Sun; Xin Jin; Lin Cheng; Xiaoyuan He; Luqiao Wang; Ting Yuan; Cuicui Lyu; Mingfeng Zhao
Journal:  Front Oncol       Date:  2019-08-19       Impact factor: 6.244

Review 10.  Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.

Authors:  Bruce D Cheson; Wolfram Brugger; Gandhi Damaj; Martin Dreyling; Brad Kahl; Eva Kimby; Michinori Ogura; Eckhart Weidmann; Clemens-Martin Wendtner; Pier Luigi Zinzani
Journal:  Leuk Lymphoma       Date:  2015-11-23
View more
  1 in total

1.  Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.

Authors:  Max S Topp; Herbert Eradat; Axel Florschütz; Andreas Hochhaus; Tomasz Wrobel; Jan Walewski; Wanda Knopinska-Posluszny; Abraham S Kanate; Ewa Lech-Maranda; Uta Brunnberg; Surya Chitra; Tina G Nielsen; Gila Sellam; Mahesh Shivhare; Izidore S Lossos
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-18       Impact factor: 4.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.